Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05298904 · ClinicalTrials.gov registry record
Pro-active Genetic Testing in Kidney Transplant Patients
A clinical trial of Kidney Transplant, sponsored by Mayo Clinic.
- Active
- Registry status
- 177
- Enrollment target
- 1
- Study location
NCT05298904: Active study of Kidney Transplant, sponsored by Mayo Clinic.
NCT05298904 is a study of Kidney Transplant that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 177 participants, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05298904, a study of Kidney Transplant, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 177 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.
Primary Outcome
Number of subjects to have genetic mutations of cancer in kidney transplant patients receiving care at Mayo Clinic Arizona
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Genetic Health Screen Panel
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2038-03-01 |
What the registry record for NCT05298904 still lists
NCT05298904 is an observational study that tracks outcomes without assigning an intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 1,892-participant average among 30 other Kidney Transplant trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Genetic Health Screen Panel is the first listed.
NCT05298904 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05298904 about?
NCT05298904 is a clinical study titled "Pro-active Genetic Testing in Kidney Transplant Patients". The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.
What is the current status of trial NCT05298904?
This trial is currently active not recruiting. The enrollment target is 177 participants. The study started on 2022-03-28. Estimated completion is 2038-03-01.
What conditions does trial NCT05298904 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT05298904?
The interventions under investigation include: Genetic Health Screen Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05298904?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05298904 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05298904's enrollment target sits among peer trials
177 11th of 30 higher than 20 of 30 other Kidney Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
-
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
RECRUITING · Phase 3
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI